Novartis inks vaccine deal with Arabio; Medicis skin drugs boost Q3 profits 30%;

@FiercePharma: GSK chief was right about tough-to-copy Advair. News | Follow @FiercePharma

> Novartis is teaming up with Arab Company for Pharmaceutical Products (Arabio) to provide Saudi Arabia and surrounding regions with vaccines for common diseases. Report

> Medicis Pharmaceutical said its third-quarter profit grew 30 percent from a year earlier as sales of its dermatology products climbed. News

> Specialty pharmaceutical company Warner Chilcott posted a better-than-expected quarterly profit, helped by revenue from products acquired from Procter & Gamble last year, and raised its full-year adjusted earnings outlook. Article

> The name Bayer Schering Pharma will soon be no more as the German group is looking to focus on the "umbrella brand" of Bayer HealthCare. Story

> Watson Pharmaceuticals was upgraded by UBS to buy from neutral after announcing quarterly results; the firm raised its target price on Watson to $59 per share. Item

> Bayer has been accused of a "shocking error of judgment" after promotional material for its erectile dysfunction brand Levitra (vardenafil) breached the ABPI Code of Practice. News

> Attempts to revive an "unusable" Canadian law passed in 2004 to enable generic versions of patented drugs to be exported to developing countries have all but failed, to the fury of health activists. Report

> Pfizer has picked Thailand as its operations hub for animal-health products in Southeast Asia to capitalize on the region's fast-growing economies. Article

> Drugmaker Aesica is aiming to grow its share of the lucrative animal health market in the next two years and expand further into the U.S. Story

Biotech News

 @FierceBiotech: J&J drops Arena diabetes drug pact. News | Follow @FierceBiotech

 @JohnCFierce: It took a couple of days, but what started out as 900+ panel submissions for BIO 2011 have been boiled down to a select 125. Follow @JohnCFierce

> Pfizer's RA pill tasocitinib posts blockbuster PhIII results. Article 

> Lilly snags Avid Radiopharmaceuticals in $800M buyout deal. News 

> WSJ: Siga's billionaire owner could derail $2.8B drug contract. Report 

> GSK, XenoPort revise Horizant pact. Story 

> PwC: Biotechs must adapt to survive in a harsh new world. Item 

Biotech IT News

> Solutions streamline, rate AE reports. News

> Biolex gives Unithink e-PRO a trial role. Report

> Group to audit pain trials for design flaws. Story 

> NCI seeks to build informatics resource. Article 

> Book author rails against "sciencey-sounding" claims. Item

> FDA contracts for Internet support, analytics. Story

And Finally... Anyone looking for an easy way to boost brain power is likely to come across an increasingly common piece of advice: Up your intake of B vitamins. Report

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.